- Home
- RMCF vs APLM Comparison
RMCF vs APLM Comparison
Compare RMCF & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- APLM
- Stock Information
- Founded
- RMCF 1981
- APLM 2016
- Country
- RMCF United States
- APLM United States
- Employees
- RMCF N/A
- APLM N/A
- Industry
- RMCF Specialty Foods
- APLM Blank Checks
- Sector
- RMCF Consumer Staples
- APLM Finance
- Exchange
- RMCF Nasdaq
- APLM Nasdaq
- Market Cap
- RMCF 14.3M
- APLM 15.6M
- IPO Year
- RMCF N/A
- APLM N/A
- Fundamental
- Price
- RMCF $2.19
- APLM $0.14
- Analyst Decision
- RMCF
- APLM Strong Buy
- Analyst Count
- RMCF 0
- APLM 2
- Target Price
- RMCF N/A
- APLM $4.25
- AVG Volume (30 Days)
- RMCF 15.1K
- APLM 912.4K
- Earning Date
- RMCF 10-15-2024
- APLM 08-14-2024
- Dividend Yield
- RMCF N/A
- APLM N/A
- EPS Growth
- RMCF N/A
- APLM N/A
- EPS
- RMCF N/A
- APLM N/A
- Revenue
- RMCF $27,921,687.00
- APLM $2,101,000.00
- Revenue This Year
- RMCF N/A
- APLM N/A
- Revenue Next Year
- RMCF N/A
- APLM N/A
- P/E Ratio
- RMCF N/A
- APLM N/A
- Revenue Growth
- RMCF N/A
- APLM 70.54
- 52 Week Low
- RMCF $1.50
- APLM $0.11
- 52 Week High
- RMCF $5.15
- APLM $2.24
- Technical
- Relative Strength Index (RSI)
- RMCF 70.41
- APLM 45.47
- Support Level
- RMCF $1.95
- APLM $0.13
- Resistance Level
- RMCF $2.04
- APLM $0.17
- Average True Range (ATR)
- RMCF 0.09
- APLM 0.01
- MACD
- RMCF 0.03
- APLM 0.00
- Stochastic Oscillator
- RMCF 83.02
- APLM 26.03
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.